ClinicalTrials.gg
CompletedNCT00970762Updated Apr 17, 2015

Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)

A Phase 3 interventional study of Rocuronium 0.6 mg/kg intubating dose and Rocuronium 0.9 mg/kg intubating dose in Anesthesia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing general elective surgery with sevoflurane anesthesia.

Study participants received an intubating dose of a neuromuscular blocker (to enable insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed, to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular blocker (onset time) after the intubating dose was measured and compared as the primary outcome.

Read the detailed description

The TOF Watch-SX (acceleration transducer) was used in the measurement of neuromuscular blocking action.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 20 but under 65 years of age
  • (ASA) Class 1, 2 or 3 for general elective surgery
  • not considered to be pregnant
  • scheduled for elective surgery under sevoflurane or propofol anesthesia with an anticipated duration of about 1.5-3 hours
  • normal laboratory values

Exclusion criteria

Exclusion Criteria:

  • certain medical conditions or medical histories
  • receiving certain medications or treatments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Rocuronium 0.6 INT, 0.1 MNT

    Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.1 mg/kg maintenance dose

  • Experimental
    Rocuronium 0.6 INT, 0.15 MNT

    Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.15 mg/kg maintenance dose

  • Experimental
    Rocuronium 0.6 INT, 0.2 MNT

    Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.6 mg/kg intubating dose · Drug: Rocuronium 0.2 mg/kg maintenance

  • Experimental
    Rocuronium 0.9 INT, 0.1 MNT

    Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.1 mg/kg maintenance dose

  • Experimental
    Rocuronium 0.9 INT, 0.15 MNT

    Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.15 mg/kg maintenance dose

  • Experimental
    Rocuronium 0.9 INT, 0.2 MNT

    Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.

    Drug: Rocuronium 0.9 mg/kg intubating dose · Drug: Rocuronium 0.2 mg/kg maintenance

  • Active comparator
    Vecuronium 0.1 INT, 0.025 MNT

    Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.

    Drug: Vecuronium 0.1 mg/kg intubating dose · Drug: Vecuronium 0.025 mg/kg maintenance dose

Interventions

  • DrugRocuronium 0.6 mg/kg intubating dose

    Drug page: Rocuronium

    Rocuronium 0.6 mg/kg intubating dose

    Also known as: Zemuron, Org 9426

  • DrugRocuronium 0.9 mg/kg intubating dose

    Drug page: Rocuronium

    0.9 mg/kg intubating dose of rocuronium

    Also known as: Zemuron, Org 9426

  • DrugRocuronium 0.1 mg/kg maintenance dose

    Drug page: Rocuronium

    Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.

    Also known as: Zemuron, Org 9426

  • DrugRocuronium 0.15 mg/kg maintenance dose

    Drug page: Rocuronium

    Rocuronium 0.15 mg/kg maintenance dose following the intubating dose

    Also known as: Zemuron, Org 9426

  • DrugRocuronium 0.2 mg/kg maintenance

    Drug page: Rocuronium

    Rocuronium 0.2 mg/kg maintenance dose following the intubating dose

    Also known as: Zemuron, Org 9426

  • DrugVecuronium 0.1 mg/kg intubating dose

    Drug page: Vecuronium

    Vecuronium 0.1 mg/kg intubating dose

    Also known as: Norcuron

  • DrugVecuronium 0.025 mg/kg maintenance dose

    Drug page: Vecuronium

    Vecuronium 0.025 mg/kg maintenance dose following the intubating dose

    Also known as: Norcuron

06

What researchers measure

Primary outcomes

  1. Onset time of intubating dose. DESCRIPTION: The time interval between the completion of injection of the study drug (rocuronium or vecuronium) and the maximal depression of first twitch--measured via TOF Watch Sx(R)-- was defined as the onset time.

    Time frame: Day of Surgery, after injection of study drug until maximal depression of first twitch achieved

Secondary outcomes

  1. Number of subjects who achieved maximal block >=90% after the intubating dose. DESCRIPTION: Reaching a 90% depression of first twitch--measured via TOF Watch Sx(R)--was defined as achieving 90% block

    Time frame: Day of Surgery, after injection of study drug until maximal depression of first twice achieved

  2. Clinical duration after first maintenance dose. DESCRIPTION: The time interval between the completion of injection of study drug and return of first twitch to 25%(as measured by TOF Watch Sx(R)) was defined as the clinical duration.

    Time frame: Day of Surgery, after injection of study drug until return of first twitch to 25%

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Sep 2, 2009
Start
Feb 2003
Primary completionActual
Feb 2004
CompletionActual
Feb 2004
Last update
Apr 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00970762
Responsible party
Sponsor
First posted
Sep 2, 2009
Start date
Feb 2003
Primary completion
Feb 2004
Completion
Feb 2004
Last update
Apr 17, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Start the discussion